尚緯股份:重要股東再度增持,結構優化穩經營增信心
福華化學通過司法拍賣以1.84億元獲得尚緯股份(603333.SH)3600萬股,占上市公司總股本的5.79%。此次增持後,其總持股比例將升至25.35%。 在實控人股權質押比例高、經營面臨挑戰的當下,福華化學的深度介入能夠有效穩定上市公司經營,強化市場信心,為尚緯股份後續業務拓展奠定穩固基礎,助力其在市場中穩步前行。與此同時,樂山國資平台(樂山高新投)此前已入駐尚緯股份,雙方協同將進一步鞏固股東結構穩定性,釋放出長期向好的積極信號。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.